ALTAIRE Pharmaceuticals, Inc P. B. Box 849 311 West Lane Aquebogue, N. Y. 11931

Telephone: 631-722-5988 · Telefax: 631-722-9683

Product Name: Fluorescein Sodium & Benoxinate HCl Ophthalmic Solution

Safety Data Sheet

Date last revised: Initial

Page 1 of 8

I. Identification

- (a) Product Identifier used on the label: Fluorescein Sodium & Benoxinate HCl Ophthalmic Solution
- (b) Other means of identification: Carton
- (c) Recommended use of the Chemicals and restrictions on use; None
- (d) Name, address, and telephone number of the chemical manufacturer, importer or other responsible party: ALTAIRE Pharmaceuticals, Inc. P. O. Box 849 · 311 West Lane Aquebogue, N. Y. 11931 631-722-5988
- e) Emergency phone number: 631-722-5988

2. Hazard(s) Identification

- (a) Classification of the chemical in accordance with paragraph(d) of §1910.1200; Mixture
- (b) Signal word hazard statement(s), symbol(s) and precautionary statement(s) in accordance with paragraph (f) of §1910.1200. (Hazard symbols may be provided as graphical reproductions in black and white or the name of the symbol, e.g., flame, skull an crossbones); None

P. B. Box 849 311 West Lane Aquebogue, N. Y. 11931

Telephone: 631-722-5988 · Telefax: 631-722-9683

Product Name: Fluorescein Sodium & Benoxinate HCl Ophthalmic Solution

Safety Data Sheet

Page 2 of 8

- (b) Signal word hazard statement(s), symbol(s) and precautionary statement(s) in accordance with paragraph (f) of §1910.1200. (Hazard symbols may be provided as graphical reproductions in black and white or the name of the symbol, e.g., flame, skull an crossbones); None
- c) Describe any hazards not otherwise classified that have been identified during the classification process; None
- d) Where an ingredient with unknown acute toxicity used in a mixture at a concentration ≥1% and the mixture is not classified based on testing of the mixture as a whole, statement that x% of the mixture consists of ingredient(s) of unknown acute toxicity is required. None
 - Composition/Information on ingredients Except as provided paragraph § 1910.1200.

For Substances

- (a) Chemical Name; None
- (b) Common name and synonyms; None
- (c) CAS number and other unique identifiers; None
- (d) Impurities and stabilizing additives which are themselves classified and which contribute to the classification of the substance. None

ALTAIRE Pharmaceuticals, Inc P. B. Box 849 311 West Lane Aquebogue, N. Y. 11931

Telephone: 631-722-5988 · Telefax: 631-722-9683

Product Name: Fluoresceln Sodium & Benoxinate HCl Ophthalmic Solution

Safety Data Sheet

Page 3 of 8

Mixtures In addition to the information required for substances

- (a) The chemical name and concentration (exact percentage) or concentration ranges all ingredients which are classified as health hazards in accordance with paragraph (d) of § 1910.1200. and
- (1) Are present above their cut-off concentration limits; or
- (2) Present a health risk below the cut-off concentration limits.
- (B) The concentration (exact percentage) shall be specified unless a trade secret claim is made in accordance with paragraph § 1910.1200, when there is batch-to-batch variability in the production of a mixture, or for a group of substantially similar mixtures (See A. 0. 5. 1.2) with similar chemical composition. In these cases, concentration ranges may be used.

For All Chemicals Where a Trade Secret is Claimed

Where a trade secret is claimed in accordance with paragraph (I) § 1910.1200, a statement that a specific chemical identity and/or exact percentage (concentration) of comparison has been withheld as a trade secret is required,

4. First Aid Measures

- a) Description of necessary measures, subdivided according to the different routes of exposure I. e., inhalation, skin and eye contact, and ingestion; For use in the eye(s) only.
- b) Most important symptoms/effects, acute and delayed. None


ALTAIRE Pharmaceuticals, Inc P. B. Box 849 311 West Lane Aquebogue, N. Y. · 11931

Telephone: 631-722-5988 · Telefax: 631-722-9683

Product Name: Fluorescein Sodium & Benoxinate HCl Ophthalmic Solution

Safety Data Sheet

Page 4 of 8



P. B. Box 849 311 West Lane Aquebogue, N. Y. · 11931

Telephone: 631-722-5988 · Telefax: 631-722-9683

Product Name: Fluorescein Sodium & Benoxinate HCl Ophthalmic Solution

Safety Data Sheet

Page 5 of 8

- (b) Appropriate engineering controls. N/A
- (c) Individual protection measures, such as personal protective equipment. N/A
 - 9. Physical and Chemical properties
 - (a) Appearance(physical state, color, etc.); Yellow to orange red, mobile liquid (strongly fluorescent)
 - (b) Odor; None
 - (c) Odor threshold; N/A
 - (d) ph Between: 4.3 AND 5.3
 - (e) Melting point/freezing point; N/A
- (f) Initial boiling point and boiling range: N/A
- (g) Flash point: N/A
- (h) Evaporation rate; N/A
- (i) Flammability (solid, gas); N/A
- (j) Upper/lower flammability or explosive limits; N/A
- (k) Vapor pressure; N/A
- (I) Vapor density; N/A
- (m) Relative density; N/A

ALTAIRE Pharmaceuticals, Inc P. B. Box 849 311 West Lane

Aquebogue, N. Y. · 11931 Telephone: 631-722-5988 · Telefax: 631-722-9683

Product Name: Fluorescein Sodium & Benoxinate HCl Ophthalmic Solution

Safety Data Sheet

Page 6 of 8

- (n) Suitability(ies); N/A
- (o) Auto-ignition temperature; N/A
- (p) Viscosity; N/A
- (q) Viscosity; N/A

10. Stability and reactivity

- (a) Reactivity; N/A
- (b) Chemical Stability; N/A
- (c) Possibility of hazardous reactions; N/A
- (d) Conditions to avoid (e.g., static discharge, shock, or vibration); N/A
- (e) Incompatible materials; N/A
- (f) Hazardous decomposition products. N/A

11. Toxicological information

Description of the various toxicological (health) effects and the available data used to identify those effects, including;

- (a) Information on the likely routes of exposure (inhalation, ingestion, skin and eye contact); For use in eye(s) only.
- (b) Symptoms related to the physical, chemical and toxicological characteristics; N/A

ALTAIRE Pharmaceuticals, Inc P. B. Box 849 311 West Lane Aquebogue, N. Y. 11931

Telephone: 631-722-5988 · Telefax: 631-722-9683

Product Name: Fluorescein Sodium & Benoxinate HCI Ophthalmic Solution

Safety Data Sheet

Page 7 of 8

- (c)Delayed and immediate effects and also chronic effects from short- and long term exposure; N/A
- d) Numerical measures of toxicity (such as acute toxicity estimates).
 N/A
- (e) Whether the hazardous chemical is listed in the National Toxicology Program (NTP) Report on Carcinogens (latest edition) or has been found to be a potential carcinogen in the International Agency for Research on Cancer (IARC) monograph)latest edition), or by OSHA, N/A

12. Ecological information (Non-mandatory)

- (a) Ecotoxicity (aquatic and terrestrial, where available); N/A
- (b) Persistence and degradability; N/A
- (c) Bioacumulative potential; N/A
- (d) Mobility in soil; N/A
- (e) Other adverse effects (such as hazardous to the ozone layer). N/A

13. Disposable considerations (Non-mandatory)

Description of waste residues and information on their safe handling and methods of disposal, including the disposal of any contaminated packaging. Waste must be disposed of in accordance with federal, state and local environmental control regulations.

ALTAIRE Pharmaceuticals, Inc P. B. Box 849 311 West Lane Aquebogue, N. Y. · 11931

Telephone: 631-722-5988 · Telefax: 631-722-9683

Product Name: Fluorescein Sodium & Benoxinate HCl Ophthalmic Solution

Safety Data Sheet

Page 8 of 8

14. Transport information (Non-mandatory)
(a) UN Number; N/A
(b) UN proper shipping name; N/A
(c) Transport hazard class(es); N/A
d) Packaging group, if applicable; N/A
(e) Environmental hazards (e.g., Marine pollutant (Yes/No); N/A
(f) Transport in bulk (according to Annex II of MARPOL 73/78 and the ib Code; N/A
(g) Special precautions which a user needs to be aware of, or needs to comply within connection with transport or conveyance either within or outside their premises. N/A
15. Regulatory information (Non-mandatory)
Safety, health and environmental regulations specific for the product in question.
16. Other information, including date of preparation 06/11/14.
The date of preparation of the Safety Data Sheet 06/11/14. Written by Ablian Jalian 6/11/14 Reviewed by: State Arragach 06/14/14